1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

Completed · Phase 3 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease

In brief

This study was designed to investigate the 1 year efficacy and safety of the 50 µg once daily (od) dose of glycopyrronium bromide (NVA237) in patients with moderate to severe chronic obstructive pulmonary disease.

Key facts

Study ID

NCT00929110

Run by

Novartis

People needed

1066

Starts

2009-06-01

Expected to finish

2011-04-01

Last updated by the study team

2012-08-17

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female adults aged ≥ 40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure.
• Patients with moderate to severe stable chronic obstructive pulmonary disease (COPD, Stage II or Stage III) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines 2008.
• Current or ex-smokers who have a smoking history of at least 10 pack years.
• Patients with a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 30% and < 80% of the predicted normal, and post-bronchodilator FEV1/forced vital capacity (FVC) < 0.7 at Visit 2 (Day -14).
• Patients, according to daily electronic diary data between Visit 2 (Day -14) and Visit 3 (Day 1), with a total score of 1 or more on at least 4 of the last 7 days prior to Visit 3 (Day 1).

You may not qualify if…

• Pregnant women or nursing mothers (pregnancy confirmed by positive urine pregnancy test).
• Women of child-bearing potential, unless using an approved method of medical or surgical contraception.
• Patients requiring long term oxygen therapy (> 15 h a day) on a daily basis for chronic hypoxemia, or who have been hospitalized for an exacerbation of their airways disease in the 6 weeks prior to Visit 1 (Day -21) or between Visit 1 (Day -21) and Visit 3 (Day 1).
• Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1 (Day -21).
• Patients who, in the judgment of the investigator or the responsible Novartis personnel, have a clinically relevant laboratory abnormality or a clinically significant condition.
• Patients with any history of asthma indicated by (but not limited to) a blood eosinophil count > 600/mm\^3 (at Visit 1, Day -21) and onset of symptoms prior to age 40 years.
• Patients with a history of long QT syndrome or whose QTc measured at Visit 1 (Day -21) (Fridericia method) is prolonged (> 450 ms for males or > 470 ms for females.
• Other protocol-defined inclusion/exclusion criteria may apply to the study.

Where it is running

• Novartis Investigative Site — Mobile, Alabama, United States
• Novartis Investigative Site — Montgomery, Alabama, United States
• Novartis Investigator Site — Fort Smith, Arkansas, United States
• Novartis Investigator Site — Anaheim, California, United States
• Novartis Investigative Site — Fullerton, California, United States
• Novartis Investigative Site — Lakewood, California, United States
• Novartis Investigator Site — Los Angeles, California, United States
• Novartis Investigator Site — Los Angeles, California, United States
• Novartis Investigator Site — Mission Viejo, California, United States
• Novartis Investigator Site — Paramount, California, United States
• Novartis Investigator Site — Riverside, California, United States
• Novartis Investigative Site — Rolling Hills Estates, California, United States
• Novartis Investigator Site — San Diego, California, United States
• Novartis Investigator Site — Colorado Springs, Colorado, United States
• Novartis Investigative site — DeLand, Florida, United States
• Novartis Investigative Site — Fort Lauderdale, Florida, United States
• Novartis Investigative Site — Miami, Florida, United States
• Novartis Investigative Site — Miami Beach, Florida, United States
• Novartis Investigative Site — Ocala, Florida, United States
• Novartis Investigative Site — Panama City, Florida, United States
• Novartis Investigative Site — Tampa, Florida, United States
• Novartis Investigator Site — Winter Park, Florida, United States
• Novartis Investigative Site — Atlanta, Georgia, United States
• Novartis Investigative Site — Blue Ridge, Georgia, United States
• Novartis Investigative Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.